Author: Aran Singanayagam; Joseph Footitt; Benjamin T Kasdorf; Matthias Marczynski; Michael T Cross; Lydia J Finney; Maria-Belen Trujillo Torralbo; Maria Calderazzo; Jie Zhu; Julia Aniscenko; Thomas B Clarke; Philip L Molyneaux; Nathan W Bartlett; Miriam F Moffatt; William O Cookson; Jadwiga Wedzicha; Christopher M Evans; Oliver Lieleg; Patrick Mallia; Sebastian L Johnston
Title: MUC5AC drives COPD exacerbation severity through amplification of virus-induced airway inflammation Document date: 2019_7_22
ID: gg2ctmn7_8
Snippet: We initially evaluated the expression of the major mucin glycoproteins MUC5AC and MUC5B in sputum samples taken from COPD patients during virus-associated naturallyoccurring exacerbations (Fig.1a) in our community-based cohort study. A total of 27 exacerbations were reported, of which 18 exacerbations (67%) were associated with positive virus detection by PCR of sputum samples (rhinovirus n=11, coronavirus n=4, RSV n=2, influenza n=1) as previous.....
Document: We initially evaluated the expression of the major mucin glycoproteins MUC5AC and MUC5B in sputum samples taken from COPD patients during virus-associated naturallyoccurring exacerbations (Fig.1a) in our community-based cohort study. A total of 27 exacerbations were reported, of which 18 exacerbations (67%) were associated with positive virus detection by PCR of sputum samples (rhinovirus n=11, coronavirus n=4, RSV n=2, influenza n=1) as previously reported. 13 These 18 virus-positive exacerbation samples were used for analyses (see Table 1 for the clinical characteristics of the subjects reporting these 18 exacerbations). Significant increases from baseline were observed for sputum supernatant MUC5AC protein concentrations at exacerbation presentation and at 2 weeks during exacerbation with no significant increase observed for MUC5B protein (Fig.1b) .
Search related documents:
Co phrase search for related documents- baseline significant increase and exacerbation presentation: 1
- baseline significant increase and significant increase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
- clinical characteristic and cohort study: 1, 2
- clinical characteristic and copd patient: 1
- clinical characteristic and previously report: 1
- clinical characteristic and significant increase: 1
- clinical characteristic and virus detection: 1, 2, 3, 4
- cohort study and community base: 1
- cohort study and copd patient: 1
- cohort study and exacerbation presentation: 1
- cohort study and mucin glycoprotein: 1
- cohort study and significant increase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- cohort study and sputum sample: 1
- cohort study and virus detection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- copd patient and significant increase: 1
- copd patient and sputum sample: 1
- copd patient and virus detection: 1
- exacerbation presentation and significant increase: 1
- exacerbation presentation and virus detection: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date